



**Selenium, Ltd. Awarded NIH Research Grant to Develop
Antimicrobial Dental Devices and Water Lines**

The two-year \$912,943 grant supports the company's novel coating technology for safer, more effective and less expensive antimicrobial applications.

Lubbock, TX and Austin, TX -- April 28, 2010 -- The National Institute of Dental and Craniofacial Research (NIDCR), one of the National Institutes of Health (NIH), has issued a two-year \$912,943 grant to biopharmaceutical company Selenium, Ltd. to support the development of antimicrobial dental devices and water lines. In the two-part grant the NIH has approved \$492,972 for year one and \$419,971 for year two dependent on achieving year one objectives. The company's SeLECT™ technology addresses the need for a safer, more effective and less costly antimicrobial or antineoplastic coating technology that can reduce the risk of contamination or infection in the dentist office.

"This grant is great validation of the importance and novelty of our technology for dental and medical applications. It will enable us to continue our work with SeLECT technology for innovative antimicrobial coatings in dental water line tubing. This can have an impact on the global dental industry and greatly benefit both dental practitioners and dental patients," said Kris Looney, President of Selenium, Ltd.

Selenium, Ltd. is funded and managed by Emergent Technologies, Inc, (ETI). Thomas A. Harlan, ETI Chief Executive Officer, added, "Selenium continues to receive recognition for its groundbreaking technology, and, in a very competitive funding environment, continues to receive grants that will facilitate developing the full potential of this dynamic technology platform."

Market Development

SeLECT technology was originally developed by Dr. Ted Reid and Dr. Julian Spalholz, Co-Chief Scientists of Selenium and professors within the Texas Tech University System. Selenium Ltd.'s proprietary chemistry is a "green technology." The technology is able to inhibit microbial growth on surfaces through a natural, safe catalytic reaction that does not leach chemicals or toxins into the surrounding environment. Target markets for SeLECT technology include orthodontic, ophthalmic, and other medical device coatings. The world market for medical device coatings could exceed \$7.5bn by the year 2015, according to a new report by US firm Global Industry Analysts,

--more--

Page 2 of 2
Selenium, Ltd. Awarded NIH Research Grant to Develop
Antimicrobial Dental Devices and Water Lines

and represents multiple growth opportunities for Selenium. Selenium has already made its presence felt in the global dental marketplace through the company's co-development agreement with leading orthodontic supplier Element 34 Technologies (formerly ClassOne Orthodontics, Inc.). Together they created SeLECT Defense™, innovative antimicrobial orthodontics that prevent bacteria and plaque buildup, based on Selenium's technology platform. The FDA-approved SeLECT Defense is being marketed worldwide by Element 34 Technologies in more than 30 countries.

About Selenium, Ltd.

Selenium, Ltd. was founded in 2004 based on discoveries made by Julian Spallholz, Ph.D. and Ted Reid, Ph.D. at Texas Tech University. Their work revealed that certain organo-selenium molecules are catalytic and produce super oxide radicals, resulting in a lethal, but short-range toxicity to surrounding cells. Thus, selenium-coated surfaces act as an impenetrable barrier to microbes and other cells, and selenium-armed molecules will selectively destroy targeted cells. Selenium, Ltd. is an Emergent Technologies Inc. (ETI) portfolio company, and ETI provides all management services. For more information, visit the company website www.selenbio.com.

About Emergent Technologies, Inc.

Emergent Technologies, Inc. (ETI) is a life sciences technology investment and management company which provides early stage funding and development for scientific discoveries originating at universities and research institutions. The Company creates value by transforming scientific breakthroughs into technology platforms with multiple applications. ETI's unique innovation process enables the Company to select promising scientific discoveries for development, maximize the value of intellectual property and manage both cost and risk associated with the commercial development of early stage technologies. ETI is dedicated to turning research into revenue and, in the process, introducing compelling solutions to meet important market needs. For more information, visit the company website www.etibio.com.

###

Media Contact:

Sandra Oak
Nsight Public Relations
Phone: 321-591-1508
soak@nsightpr.com